Top-Rated StocksTop-RatedNASDAQ:MRUS Merus (MRUS) Stock Price, News & Analysis → Gold Set to EXPLODE! (From Gold Safe Exchange) (Ad) Free MRUS Stock Alerts $53.24 -4.06 (-7.09%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$52.78▼$57.9850-Day Range$39.81▼$59.9952-Week Range$19.81▼$61.61Volume1.72 million shsAverage Volume750,925 shsMarket Capitalization$3.12 billionP/E RatioN/ADividend YieldN/APrice Target$63.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Merus alerts: Email Address Merus MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside19.8% Upside$63.80 Price TargetShort InterestBearish5.93% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.40Based on 28 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.15) to ($2.82) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.73 out of 5 starsMedical Sector698th out of 929 stocksPharmaceutical Preparations Industry326th out of 438 stocks 3.5 Analyst's Opinion Consensus RatingMerus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 12 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMerus has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Merus' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.93% of the outstanding shares of Merus have been sold short.Short Interest Ratio / Days to CoverMerus has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Merus has recently increased by 2.96%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldMerus does not currently pay a dividend.Dividend GrowthMerus does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MRUS. Previous Next 3.0 News and Social Media Coverage News SentimentMerus has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.83 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 28 news articles for Merus this week, compared to 3 articles on an average week.Search Interest18 people have searched for MRUS on MarketBeat in the last 30 days. This is an increase of 350% compared to the previous 30 days.MarketBeat Follows9 people have added Merus to their MarketBeat watchlist in the last 30 days. This is an increase of 350% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Merus insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.57% of the stock of Merus is held by insiders.Percentage Held by Institutions96.14% of the stock of Merus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Merus' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Merus are expected to grow in the coming year, from ($3.15) to ($2.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Merus is -19.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Merus is -19.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMerus has a P/B Ratio of 8.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Merus' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeGold Set to EXPLODE!Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! About Merus Stock (NASDAQ:MRUS)Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Read More MRUS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MRUS Stock News HeadlinesMay 31 at 1:58 AM | americanbankingnews.comQ1 2025 EPS Estimates for Merus (NASDAQ:MRUS) Lowered by William BlairMay 30 at 2:34 AM | americanbankingnews.comStifel Nicolaus Increases Merus (NASDAQ:MRUS) Price Target to $90.00May 29 at 9:30 PM | globenewswire.comMerus Announces Pricing of Upsized Public Offering of Common SharesMay 29 at 4:59 PM | markets.businessinsider.comBuy Rating Affirmed for Merus with Increased Price Objective Amid Promising Peto’ Efficacy and Market PotentialMay 29 at 4:59 PM | finance.yahoo.comThese Analysts Think Merus N.V.'s (NASDAQ:MRUS) Sales Are Under ThreatMay 29 at 8:00 AM | globenewswire.comMerus to Participate in a Fireside Chat at the Jefferies Global Healthcare ConferenceMay 29 at 2:56 AM | americanbankingnews.comMerus (NASDAQ:MRUS) Price Target Raised to $93.00May 29 at 1:28 AM | americanbankingnews.comMerus (NASDAQ:MRUS) Sees Large Volume Increase After Analyst UpgradeMay 28 at 4:01 PM | globenewswire.comMerus N.V. Announces Proposed Public Offering of Common SharesMay 28 at 7:43 AM | finance.yahoo.comMerus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCCMay 28 at 7:00 AM | globenewswire.comMerus' Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCCMay 26, 2024 | americanbankingnews.comMerus (NASDAQ:MRUS) Price Target Raised to $61.00May 26, 2024 | americanbankingnews.comMerus (NASDAQ:MRUS) Stock Rating Reaffirmed by HC WainwrightMay 26, 2024 | americanbankingnews.comMerus (NASDAQ:MRUS) Rating Reiterated by Needham & Company LLCMay 25, 2024 | americanbankingnews.comMerus (NASDAQ:MRUS) Hits New 12-Month High After Analyst UpgradeMay 25, 2024 | americanbankingnews.comInvestors Purchase High Volume of Merus Put Options (NASDAQ:MRUS)May 24, 2024 | barrons.comMerus Clears Wall Street's Bar With Cancer DataMay 24, 2024 | seekingalpha.comMerus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy)May 24, 2024 | finance.yahoo.comWhy Is Cancer-Focused Merus Stock Trading Over 30% On Friday?May 24, 2024 | msn.comMerus rallies on publication of oncology study abstractsMay 24, 2024 | markets.businessinsider.comMerus’s Petosemtamab Shows Promising Trial Results, Analyst Recommends Buy with $54 Price TargetMay 24, 2024 | investors.comWhy Top 4% Biotech Stock, Merus, Just Catapulted To A Record HighMay 23, 2024 | finanznachrichten.deMerus N.V.: Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual MeetingMay 23, 2024 | globenewswire.comMerus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual MeetingMay 23, 2024 | globenewswire.comMerus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual MeetingSee More Headlines Receive MRUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Merus and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today5/31/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MRUS CUSIPN/A CIK1651311 Webwww.merus.nl Phone(130) 253-8800FaxN/AEmployees172Year FoundedN/APrice Target and Rating Average Stock Price Target$63.80 High Stock Price Target$93.00 Low Stock Price Target$45.00 Potential Upside/Downside+13.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($2.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-154,940,000.00 Net Margins-390.36% Pretax Margin-377.98% Return on Equity-44.13% Return on Assets-33.08% Debt Debt-to-Equity RatioN/A Current Ratio5.23 Quick Ratio5.23 Sales & Book Value Annual Sales$43.95 million Price / Sales75.20 Cash FlowN/A Price / Cash FlowN/A Book Value$5.95 per share Price / Book9.46Miscellaneous Outstanding Shares58,690,000Free Float56,006,000Market Cap$3.30 billion OptionableOptionable Beta1.10 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Sven Ante Lundberg M.D. (Age 61)CEO, President & Executive Director Comp: $953.06kMr. Gregory D. Perry (Age 64)Chief Financial Officer Comp: $63.76kMr. Peter B. Silverman J.D. (Age 46)EVP, Company Secretary, COO, General Counsel, Chief Intellectual Property Officer & Head of US Legal Comp: $601.19kDr. Hui Liu Ph.D. (Age 57)Chief Business Officer, Executive VP & Head of Merus U.S. Comp: $597.7kDr. Andrew Joe M.D. (Age 57)Chief Medical Officer & Senior VP Comp: $692.74kDr. Hennie HoogenboomCo-Founder and Scientific AdvisorHarry ShumanChief Accounting OfficerMr. Cornelis Adriaan de Kruif Ph.D. (Age 59)CTO & Executive VP Comp: $350.85kDr. Cecilia Anna Wilhelmina Geuijen Ph.D.Chief Scientific Officer & Senior VPKathleen FarrenIR & Corporate Communications OfficerMore ExecutivesKey CompetitorsViatrisNASDAQ:VTRSUnited TherapeuticsNASDAQ:UTHRDr. Reddy's LaboratoriesNYSE:RDYSarepta TherapeuticsNASDAQ:SRPTCatalentNYSE:CTLTView All CompetitorsInsiders & InstitutionsLynx1 Capital Management LPBought 373,782 shares on 5/30/2024Ownership: 2.571%Virtu Financial LLCBought 12,321 shares on 5/20/2024Ownership: 0.021%Artal Group S.A.Bought 455,081 shares on 5/17/2024Ownership: 0.775%Janus Henderson Group PLCBought 11,536 shares on 5/16/2024Ownership: 0.924%California State Teachers Retirement SystemBought 936 shares on 5/16/2024Ownership: 0.057%View All Insider TransactionsView All Institutional Transactions MRUS Stock Analysis - Frequently Asked Questions Should I buy or sell Merus stock right now? 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MRUS shares. View MRUS analyst ratings or view top-rated stocks. What is Merus' stock price target for 2024? 12 brokers have issued twelve-month price objectives for Merus' stock. Their MRUS share price targets range from $45.00 to $93.00. On average, they anticipate the company's share price to reach $63.80 in the next twelve months. This suggests a possible upside of 19.8% from the stock's current price. View analysts price targets for MRUS or view top-rated stocks among Wall Street analysts. How have MRUS shares performed in 2024? Merus' stock was trading at $27.50 at the beginning of 2024. Since then, MRUS shares have increased by 93.6% and is now trading at $53.24. View the best growth stocks for 2024 here. When is Merus' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our MRUS earnings forecast. How were Merus' earnings last quarter? Merus (NASDAQ:MRUS) issued its quarterly earnings results on Wednesday, May, 8th. The biotechnology company reported ($0.59) EPS for the quarter, topping analysts' consensus estimates of ($0.83) by $0.24. The biotechnology company earned $7.89 million during the quarter, compared to analyst estimates of $8.94 million. Merus had a negative net margin of 390.36% and a negative trailing twelve-month return on equity of 44.13%. What ETFs hold Merus' stock? ETFs with the largest weight of Merus (NASDAQ:MRUS) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Range Cancer Therapeutics ETF (CNCR), Loncar China Biopharma ETF (CHNA), Tema Oncology ETF (CANC), BlackRock Future Health ETF (BMED) and First Trust Nasdaq Pharmaceuticals ETF (FTXH). What other stocks do shareholders of Merus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Merus investors own include Pfizer (PFE), Micron Technology (MU), OPKO Health (OPK), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Five Prime Therapeutics (FPRX) and Fulcrum Therapeutics (FULC). When did Merus IPO? Merus (MRUS) raised $64 million in an initial public offering (IPO) on Thursday, May 19th 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers. Who are Merus' major shareholders? Merus' stock is owned by many different retail and institutional investors. Top institutional investors include Lynx1 Capital Management LP (2.57%), Price T Rowe Associates Inc. MD (2.02%), BVF Inc. IL (2.00%), Medicxi Ventures Management Jersey Ltd (1.99%), Janus Henderson Group PLC (0.92%) and Artal Group S.A. (0.78%). Insiders that own company stock include Bvf Partners L P/Il, Harry Shuman, Kruif John De, Lex Bakker, Peter B Silverman and Sven Ante Lundberg. View institutional ownership trends. How do I buy shares of Merus? Shares of MRUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MRUS) was last updated on 5/31/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressShocking $16T Elon Musk Crypto LeakCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarGold Set to EXPLODE!Gold Safe ExchangeDo This Before July 30 2024 To Claim Trump’s Gift Wealthpin ProA once-in-a-century profit opportunity?Digital Mavericks Media ‘America’s Top Trader’ Who Predicted the Biggest Financial Events of The Last 30 Years, Issues New WARNING:InvestorPlaceNYSE biotech company's drug could be as revolutionary as penicillin!Financial Markets Daily Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merus Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.